6451-86-1

Basic information

• Product Name: 2-Bromo-4-methoxy-5-(benzyloxy)benzaldehyde
• Synonyms: 2-BROMO-4-METHOXY-5-(BENZYLOXY)BENZALDEHYDE;6-BROMOBENZYL ISOVANILLIN;5-BENZYLOXY-2-BROMO-4-METHOXY-BENZALDEHYDE;5-Benzyl-2-bromo-4-methoxylbenzaldehyde;2-Bromo-4-methoxy-5-;Benzaldehyde,2-broMo-4-Methoxy-5-(;2-broMo-4-Methoxy-benzyloxybenzaldehyde
• CAS NO: 6451-86-1
• Molecular Formula: C₁₅H₁₃BrO₃
• Molecular Weight: 321.17
• Product Categories: Fluorobenzene;Multisubstituted Benzene;Aromatic Aldehydes & Derivatives (substituted)
• Mol File: 6451-86-1.mol
• Article Data: 28

Chemical Properties

• Melting Point: 142.4-143.3 °C(Solv: hexane (110-54-3); ethyl acetate (141-78-6))
• Boiling Point: 427.5 °C at 760 mmHg
• Flash Point: 212.3 °C
• Appearance: /
• Density: 1.421 g/cm³
• Vapor Pressure: 1.63E-07mmHg at 25°C
• Refractive Index: 1.611
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Bromo-4-methoxy-5-(benzyloxy)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-4-methoxy-5-(benzyloxy)benzaldehyde(6451-86-1)
• EPA Substance Registry System: 2-Bromo-4-methoxy-5-(benzyloxy)benzaldehyde(6451-86-1)

Safety Data

• Hazardous Substances Data: 6451-86-1(Hazardous Substances Data)

Usage

Uses

6-Bromobenzylisovanillin is an intermediate in the synthesis of 3,8-Dihydroxy-9-methoxy-6H-Dibenzo[b,d]pyran-6-one (D455545) which has been used in anti-wrinkle agents and is known as a collagen production promoter, MMP-1 production inhibitor and elastase activity inhibitor containing urolithin.

InChI:InChI=1/C15H13BrO3/c1-18-14-8-13(16)12(9-17)7-15(14)19-10-11-5-3-2-4-6-11/h2-9H,10H2,1H3

Upstream product

• 6346-05-0 3-benzyloxy-4-methoxybenzaldehyde 
• 120-57-0 piperonal 
• 2973-59-3 2-bromoisovanillin 
• 108-95-2 phenol 
• 100-51-6 benzyl alcohol 
• 15930-53-7 6-bromo-3,4-methylenedioxybenzaldehyde 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 621-59-0 isovanillin 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 5392-10-9 2-bromo-4,5-dimethoxybenzaldehyde 
• 40705-20-2 3-benzyloxy-6-bromo-4-hydroxybenzaldehyde 
• 77-78-1 dimethyl sulfate 
• 69048-79-9 4-bromo-5-formyl-2-methoxyphenyl acetate 

Downstream Products

• 697803-43-3 (E)-3-benzyloxy-6-bromo-4-methoxy-β-chlorostyrene 
• 796843-30-6 4-benzyloxy-5,2',3',4'-tetramethoxy-biphenyl-2-carbaldehyde 
• 796843-31-7 4-benzyloxy-5,2',4'-trimethoxy-biphenyl-2-carbaldehyde 
• 918896-59-0 1-benzyloxy-4-bromo-2-methoxy-5-(2-nitro ethyl)benzene 
• 918896-60-3 2-[2-bromo-4-methoxy-5-benzyloxy]-1-(tert-butoxycarbonyl amino)-ethane 
• 1026439-42-8 (E)-3-[2-(2-Amino-ethyl)-4-benzyloxy-5-methoxy-phenyl]-acrylic acid ethyl ester 
• 1026556-60-4 (6-benzyloxy-7-methoxy-1,2,3,4-tetrahydro-isoquinolin-1-yl)-acetic acid ethyl ester 
• 918896-63-6 6-benzyloxy-1-(2-hydroxy-ethyl)-7-methoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 918896-62-5 6-benzyloxy-1-ethoxycarbonylmethyl-7-methoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 918896-61-4 2-[2-(ethylpropionate)-4-methoxy-5-benzyloxy]-1-(tert-butoxycarbonyl-amino)-ethane 
• 918896-64-7 6-benzyloxy-1-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-7-methoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 
• 141035-23-6 5-Benzyloxy-2-brom-4-methoxy-phenaethylamin 
• 24958-42-7 2-bromo-4-methoxy-5-benzyloxy-benzoic acid 
• 27240-64-8 5-Benzyloxy-2-bromo-4-methoxybenzoylchlorid 

Relevant articles and documents

On the chloride lability in electron-rich second-generation ruthenium benzylidene complexes

A series of electron-rich second-generation cis-dichloro ruthenium aldehyde-chelating benzylidene complexes was prepared, characterized, and tested in typical ring-opening metathesis polymerization (ROMP) experiments. The benzylidene precursors were prepa

DIMERIC COMPOUNDS AS STING AGONISTS

The present disclosure relates to dimeric STING agonists of Formulae (I), (II), (III), (IV), (V), and (VI), and pharmaceutically acceptable salts thereof. The present disclosure also relates to methods of preparing the compounds and methods of using the c

Fused tricyclic compounds and application thereof in medicaments

The invention relates to fused tricyclic compounds and an application thereof in medicaments, and in particular to an application of the fused tricyclic compounds in medicaments for treating and/or preventing hepatitis B. In particular, the invention rela